Literature DB >> 18580615

Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.

Judith A Cook1, Jane K Burke-Miller, Mardge H Cohen, Robert L Cook, David Vlahov, Tracey E Wilson, Elizabeth T Golub, Rebecca M Schwartz, Andrea A Howard, Claudia Ponath, Michael W Plankey, Alexandra M Levine, Andrea Levine, Dennis D Grey.   

Abstract

BACKGROUND: Longitudinal associations between patterns of crack cocaine use and progression of HIV-1 disease are poorly understood, especially among women. This study explores relationships between crack use and HIV-1 disease outcomes in a multicenter cohort of infected women.
METHODS: Subjects were 1686 HIV-seropositive women enrolled at six US research centers in the Women's Interagency HIV Study. Approximately 80% were non-white and 29% used crack during the study period. Cox survival and random regression analysis examined biannual observations made April 1996 through September 2004. Outcome measures included death due to AIDS-related causes, CD4 cell count, HIV-1 RNA level, and newly acquired AIDS-defining illnesses.
RESULTS: Persistent crack users were over three times as likely as non-users to die from AIDS-related causes, controlling for use of HAART self-reported at 95% or higher adherence, problem drinking, age, race, income, education, illness duration, study site, and baseline virologic and immunologic indicators. Persistent crack users and intermittent users in active and abstinent phases showed greater CD4 cell loss and higher HIV-1 RNA levels controlling for the same covariates. Persistent and intermittent crack users were more likely than non-users to develop new AIDS-defining illnesses controlling for identical confounds. These results persisted when controlling for heroin use, tobacco smoking, depressive symptoms, hepatitis C virus coinfection, and injection drug use.
CONCLUSION: Use of crack cocaine independently predicts AIDS-related mortality, immunologic and virologic markers of HIV-1 disease progression, and development of AIDS-defining illnesses among women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580615      PMCID: PMC2645902          DOI: 10.1097/QAD.0b013e32830507f2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

1.  Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women.

Authors:  Tanya Telfair Sharpe; Lisa M Lee; Allyn K Nakashima; Laurie D Elam-Evans; Patricia L Fleming
Journal:  J Community Health       Date:  2004-04

2.  HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities.

Authors:  A H Kral; R N Bluthenthal; R E Booth; J K Watters
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

3.  MIXOR: a computer program for mixed-effects ordinal regression analysis.

Authors:  D Hedeker; R D Gibbons
Journal:  Comput Methods Programs Biomed       Date:  1996-03       Impact factor: 5.428

Review 4.  Acute and chronic effects of cocaine on the immune system and the possible link to AIDS.

Authors:  G C Baldwin; M D Roth; D P Tashkin
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

5.  Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study.

Authors:  P Pezzotti; N Galai; D Vlahov; G Rezza; C M Lyles; J Astemborski
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-03-01

6.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

7.  Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women.

Authors:  Lorna E Thorpe; Margaret Frederick; Jane Pitt; Irene Cheng; D Heather Watts; Shelley Buschur; Karen Green; Carmen Zorrilla; Sheldon H Landesman; Ronald C Hershow
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

8.  Evaluation of possible effects of continued drug use on HIV progression among women.

Authors:  Anne M Rompalo; Nina Shah; Joseph B Margolick; Homayoon Farzadegan; Julia Arnsten; Paula Schuman; Josiah D Rich; Lytt I Gardner; Dawn K Smith; David Vlahov
Journal:  Int J STD AIDS       Date:  2004-05       Impact factor: 1.359

9.  Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.

Authors:  Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

10.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18
View more
  120 in total

1.  Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.

Authors:  Jiaming Liang; Ekaterina Nosova; Hudson Reddon; Seonaid Nolan; Eugenia Socías; Rolando Barrios; M-J Milloy
Journal:  AIDS       Date:  2020-07-15       Impact factor: 4.177

2.  Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study.

Authors:  M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

3.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

4.  Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007-2015.

Authors:  Catherine R Lesko; Alexander P Keil; Richard D Moore; Geetanjali Chander; Anthony T Fojo; Bryan Lau
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

5.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

6.  Applying behavioral activation to sustain and enhance the effects of contingency management for reducing stimulant use among individuals with HIV infection.

Authors:  Matthew J Mimiaga; Elizabeth F Closson; David W Pantalone; Steven A Safren; Jennifer A Mitty
Journal:  Psychol Health Med       Date:  2018-09-13       Impact factor: 2.423

7.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

8.  Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy.

Authors:  Adam W Carrico; Peter W Hunt; Torsten B Neilands; Samantha E Dilworth; Jeffrey N Martin; Steven G Deeks; Elise D Riley
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

Review 9.  Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions.

Authors:  Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet
Journal:  Alcohol Clin Exp Res       Date:  2016-09-22       Impact factor: 3.455

10.  Gender-Related Risk Factors Improve Mortality Predictive Ability of VACS Index Among HIV-Infected Women.

Authors:  Mardge H Cohen; Anna L Hotton; Ronald C Hershow; Alexandra Levine; Peter Bacchetti; Elizabeth T Golub; Kathryn Anastos; Mary Young; Deborah Gustafson; Kathleen M Weber
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.